Connect Biopharma Holdings Past Earnings Performance
Past criteria checks 0/6
Connect Biopharma Holdings has been growing earnings at an average annual rate of 21.1%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 162% per year.
Key information
21.1%
Earnings growth rate
41.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 162.0% |
Return on equity | -19.4% |
Net Margin | -88.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Revenue & Expenses Breakdown
How Connect Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 24 | -21 | 14 | 39 |
31 Mar 24 | 12 | -40 | 14 | 45 |
31 Dec 23 | 0 | -60 | 15 | 52 |
30 Sep 23 | 0 | -77 | 17 | 64 |
30 Jun 23 | 0 | -93 | 19 | 76 |
31 Mar 23 | 0 | -104 | 20 | 85 |
31 Dec 22 | 0 | -118 | 21 | 97 |
30 Sep 22 | 0 | -131 | 22 | 101 |
30 Jun 22 | 0 | -114 | 22 | 96 |
31 Mar 22 | 0 | -163 | 21 | 91 |
01 Jan 22 | 0 | -202 | 19 | 80 |
30 Sep 21 | 0 | -229 | 16 | 64 |
30 Jun 21 | 0 | -255 | 14 | 48 |
31 Mar 21 | 0 | -185 | 10 | 35 |
31 Dec 20 | 0 | -119 | 7 | 23 |
31 Dec 19 | 0 | -24 | 1 | 15 |
Quality Earnings: CNTB is currently unprofitable.
Growing Profit Margin: CNTB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNTB is unprofitable, but has reduced losses over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare CNTB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CNTB has a negative Return on Equity (-19.35%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 18:53 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Connect Biopharma Holdings Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Louise Chen | Cantor Fitzgerald & Co. |
Ziyu He | China International Capital Corporation Limited |
Emily Bodnar | H.C. Wainwright & Co. |